$CHHE
China Health Industries Holdings, Inc. Stock $chhe

$chhe Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-K Financial Statement

#000121390022056075 Filed on September 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022
Revenue		$270.00	$267.00
YoY Change		-99.94%	-100.0%
Cost Of Revenue		$1.750K	$1.748K
YoY Change		-99.44%	-99.94%
Gross Profit		-$1.480K	-$1.481K
YoY Change		-101.23%	-100.04%
Gross Profit Margin		-548.15%	-554.68%
Selling, General & Admin	$334.8K	$934.9K	$934.9K
YoY Change	31.28%	228.21%	-19.98%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$155.9K	$206.1K	$711.5K
YoY Change	-25.79%	119.64%	-19.03%
% of Gross Profit
Operating Expenses	$490.7K	$1.646M	$1.646M
YoY Change	12.8%	283.97%	-7.4%
Operating Profit	-$490.7K	-$1.648M	-$1.648M
YoY Change	12.42%	433.58%	-188.41%
Interest Expense		$157.9K
YoY Change		345.93%
% of Operating Profit
Other Income/Expense, Net	$34.28K	$1.139M	$1.297M
YoY Change	-92.88%	5502.8%	6323.51%
Pretax Income	-$456.4K	-$351.0K	-$351.0K
YoY Change	-632.79%	38.68%	-117.36%
Income Tax		$2.930K	$2.934K
% Of Pretax Income
Net Earnings	-$456.4K	-$354.0K	-$354.0K
YoY Change	2033.92%	32.74%	-127.41%
Net Earnings / Revenue		-131092.59%	-132565.54%
Basic Earnings Per Share	-$0.01		-$0.01
Diluted Earnings Per Share	-$0.01	-$5.401K	-$0.01
COMMON SHARES
Basic Shares Outstanding	65.54M shares		65.54M shares
Diluted Shares Outstanding	65.54M shares		65.54M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$42.12M	$44.79M	$44.79M
YoY Change	-8.32%	1.0%	1.0%
Cash & Equivalents	$42.12M	$44.79M	$44.79M
Short-Term Investments
Other Short-Term Assets	$226.0K	$244.9K	$244.9K
YoY Change	-5.65%	0.89%	0.89%
Inventory	$469.1K	$521.2K	$521.2K
Prepaid Expenses	$23.52K	$30.00K
Receivables	$9.008K	$9.567K	$9.570K
Other Receivables	$28.66K	$31.78K	$31.78K
Total Short-Term Assets	$42.85M	$45.60M	$45.60M
YoY Change	-10.07%	-4.47%	-4.47%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.939M	$3.158M	$3.737M
YoY Change	-28.47%	-24.64%	-10.82%
Goodwill
YoY Change
Intangibles	$1.217M	$1.413M
YoY Change		-28.06%
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Total Long-Term Assets	$4.706M	$5.150M	$5.150M
YoY Change	-20.96%	-16.36%	-16.36%
TOTAL ASSETS
Total Short-Term Assets	$42.85M	$45.60M	$45.60M
Total Long-Term Assets	$4.706M	$5.150M	$5.150M
Total Assets	$47.56M	$50.75M	$50.75M
YoY Change	-11.28%	-5.83%	-5.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$309.5K	$335.0K	$335.0K
YoY Change	-504.83%	-17.66%	-17.66%
Accrued Expenses	$127.0K	$162.4K	$162.4K
YoY Change	-31.67%	-25.7%	-25.7%
Deferred Revenue
YoY Change
Short-Term Debt	$5.619M	$6.760M	$6.760M
YoY Change	-30.84%	-16.34%	-16.34%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.723M	$7.945M	$7.945M
YoY Change	-11.82%	-12.82%	-12.82%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.723M	$7.945M	$7.945M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$7.723M	$7.945M	$7.945M
YoY Change	-11.82%	-12.82%	-12.82%
SHAREHOLDERS EQUITY
Retained Earnings	$41.24M	$41.70M
YoY Change		-0.84%
Common Stock	$6.554K	$6.554K
YoY Change		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$39.84M	$42.80M	$42.80M
YoY Change
Total Liabilities & Shareholders Equity	$47.56M	$50.75M	$50.75M
YoY Change	-11.28%	-5.83%	-5.83%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022
OPERATING ACTIVITIES
Net Income	-$456.4K	-$354.0K	-$354.0K
YoY Change	2033.92%	32.74%	-127.41%
Depreciation, Depletion And Amortization	$155.9K	$206.1K	$711.5K
YoY Change	-25.79%	119.64%	-19.03%
Cash From Operating Activities	-$17.53K	-$856.2K	$2.116M
YoY Change	-100.77%	-134.71%	-61.92%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities		$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000
YoY Change
NET CHANGE
Cash From Operating Activities	-$17.53K	-856.2K	$2.116M
Cash From Investing Activities		0.000
Cash From Financing Activities		0.000
Net Change In Cash	-$2.670M	-856.2K	$443.3K
YoY Change		-134.71%
FREE CASH FLOW
Cash From Operating Activities	-$17.53K	-$856.2K	$2.116M
Capital Expenditures		$0.00
Free Cash Flow	-$17.53K	-$856.2K	$2.116M
YoY Change	-100.77%	-134.7%	-62.02%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q2	us-gaap	Inventory Net Of Allowances Customer Advances And Progress Billings InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings		usd
CY2021Q2	us-gaap	Inventory Net Of Allowances Customer Advances And Progress Billings InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings		usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2022Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-51060
CY2022	dei	Entity Registrant Name EntityRegistrantName	CHINA HEALTH INDUSTRIES HOLDINGS, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-0827216
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	3199-1 Longxiang Road
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Songbei District
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Harbin City
CY2022	dei	Entity Address Country EntityAddressCountry	CN
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	150028
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Public Float EntityPublicFloat	5436329	usd
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	65539737	shares
CY2022	dei	Auditor Firm AuditorFirmId	2769
CY2022	dei	Auditor Name AuditorName	Centurion ZD CPA & Co.
CY2022	dei	Auditor Location AuditorLocation	Hong Kong, China
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44789999	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44346744	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9567	usd
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2346867	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	521229	usd
CY2021Q2	us-gaap	Inventory Net InventoryNet	761639	usd
CY2022Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	31778	usd
CY2021Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	32850	usd
CY2022Q2	chhe	Advances To Suppliers AdvancesToSuppliers	214915	usd
CY2021Q2	chhe	Advances To Suppliers AdvancesToSuppliers	218307	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	30004	usd
CY2021Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	24466	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	45597492	usd
CY2021Q2	us-gaap	Assets Current AssetsCurrent	47730873	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3158021	usd
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3629905	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1412603	usd
CY2021Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1963516	usd
CY2022Q2	chhe	Construction In Progress ConstructionInProgress	579402	usd
CY2021Q2	chhe	Construction In Progress ConstructionInProgress	560910	usd
CY2021Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2933	usd
CY2022Q2	us-gaap	Assets Assets	50747518	usd
CY2021Q2	us-gaap	Assets Assets	53888137	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	334972	usd
CY2021Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	406821	usd
CY2022Q2	us-gaap	Other Liabilities OtherLiabilities	82323	usd
CY2021Q2	us-gaap	Other Liabilities OtherLiabilities	81449	usd
CY2022Q2	us-gaap	Customer Advances Current CustomerAdvancesCurrent	472307	usd
CY2021Q2	us-gaap	Customer Advances Current CustomerAdvancesCurrent	150504	usd
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	6759761	usd
CY2021Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	8079761	usd
CY2022Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	162431	usd
CY2021Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	218602	usd
CY2022Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	133005	usd
CY2021Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	176359	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	7944799	usd
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	9113496	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	65539737	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	65539737	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	65539737	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	65539737	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	6554	usd
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	6554	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	521987	usd
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	521987	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	538820	usd
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2156792	usd
CY2022Q2	chhe	Statutory Reserves StatutoryReserves	38679	usd
CY2021Q2	chhe	Statutory Reserves StatutoryReserves	38679	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	41696679	usd
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	42050629	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	42802719	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	44774641	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	42802719	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	44774641	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50747518	usd
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53888137	usd
CY2022	us-gaap	Revenues Revenues	267	usd
CY2021	us-gaap	Revenues Revenues	6492720	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	1748	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	2850729	usd
CY2022	us-gaap	Gross Profit GrossProfit	-1481	usd
CY2021	us-gaap	Gross Profit GrossProfit	3641991	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	934927	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1168385	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	711515	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	609698	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	1646442	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	1778083	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1647923	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	1863908	usd
CY2022	us-gaap	Interest Income Operating InterestIncomeOperating	157860	usd
CY2021	us-gaap	Interest Income Operating InterestIncomeOperating	137485	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1139746	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	20972	usd
CY2022	chhe	Bank Charges BankCharges	699	usd
CY2021	chhe	Bank Charges BankCharges	782	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1296907	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	157675	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-351016	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2021583	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2934	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	730461	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-353950	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	1291122	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	1617972	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-3815533	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1971922	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	5106655	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.0054
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.0197
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	65539737	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	65539737	shares
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	39667986	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	1291122	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	3815533	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	44774641	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-353950	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1617972	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	42802719	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-353950	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	1291122	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	830545	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	878794	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-9556	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-13666	usd
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	2860	usd
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	3334	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-215391	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-118743	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2288077	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2667083	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	114	usd
CY2021	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-2383	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	11024	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-26980	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-57912	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-36554	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	358179	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	12368	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-1057059	usd
CY2021	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	961538	usd
CY2022	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	-48844	usd
CY2021	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	-81300	usd
CY2022	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-40867	usd
CY2021	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-274131	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2115726	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	5556694	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8582	usd
CY2021	chhe	Payments To Expenditure In Construction In Progress PaymentsToExpenditureInConstructionInProgress	5073	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13655	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1672471	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2731231	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	443255	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8274270	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44346744	usd
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36072474	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44789999	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44346744	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	973420	usd
CY2021	chhe	Loan From Related Party For The Construction Of A Facility LoanFromRelatedPartyForTheConstructionOfAFacility	618827	usd
CY2021Q2	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	176359	usd
CY2022	us-gaap	Foreign Currency Translation Adjustment Description ForeignCurrencyTranslationAdjustmentDescription	For the purpose of presenting these financial statements, the Company’s assets and liabilities with functional currency of HKD are expressed in USD at the exchange rate on the balance sheet date, which was 7.8472 and 7.7658 as of June 30, 2022 and June 30, 2021, respectively; stockholder’s equity accounts are translated at historical rates, and income and expense items are translated at the weighted average exchange rates during the year, which was 7.8049 and 7.7563 for the years ended June 30, 2022 and 2021, respectively.
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates and Assumptions</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities on the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and judgments on historical experience and on various other assumptions and information that are believed to be reasonable under the circumstances. Estimates and assumptions of future events and their effects cannot be perceived with certainty and, accordingly, these estimates may change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment changes. Significant estimates and assumptions by management include, among others; useful lives of long-lived assets and intangible assets, valuation of inventory, accounts receivable and notes receivable, impairment analysis of long-lived assets, construction in progress, intangible assets and deferred taxes. While the Company believes that the estimates and assumptions used in the preparation of the financial statements are appropriate, actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the financial statements in the period they are determined to be necessary.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2021Q2	us-gaap	Inventory Net InventoryNet	761639	usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	City Area Code CityAreaCode	86-451-
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001309057
CY2022	dei	Local Phone Number LocalPhoneNumber	88100688
CY2022Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	44789999	usd
CY2021Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	44346744	usd
CY2022Q2	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	9567	usd
CY2021Q2	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	2346867	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	48769	usd
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	60394	usd
CY2022Q2	chhe	Advances To Suppliers AdvancesToSuppliers	214915	usd
CY2021Q2	chhe	Advances To Suppliers AdvancesToSuppliers	218307	usd
CY2022	chhe	Percentage Of Enterprises Tax Rate PercentageOfEnterprisesTaxRate	0.25	pure
CY2022	chhe	Income Tax Services Rate Percentage IncomeTaxServicesRatePercentage	0.16	pure
CY2022	chhe	Value Added Tax Payables ValueAddedTaxPayables	29835	usd
CY2021	chhe	Value Added Tax Payables ValueAddedTaxPayables	34697	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Concentrations of Business and Credit Risks</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of the Company’s manufacturing is located in the PRC. There can be no assurance that the Company will be able to successfully continue to manufacture its products and failure to do so would have a material adverse effect on the Company’s financial position, results of operations and cash flows. Moreover, the success of the Company’s operations is subject to numerous contingencies, some of which are beyond management’s control. These contingencies include general economic conditions, prices of raw materials, competition, governmental and political conditions, and changes in regulations. Since the Company is dependent on trade in the PRC, the Company is subject to various additional political, economic and other uncertainties. Among other risks, the Company’s operations will be subject to the risks of restrictions on transfer of funds, domestic customs, changing taxation policies, foreign exchange restrictions, and political and governmental regulations. The Company operates in China, which may give rise to significant foreign currency risks from fluctuations and the degree of volatility of foreign exchange rates between U.S. dollars and the Chinese currency RMB. The results of operations denominated in foreign currency are translated at the average rate of exchange during the reporting periods.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2014Q4	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	8000000	cny
CY2014Q4	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	1306186	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	213055	usd
CY2021Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	251989	usd
CY2022Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	90303	usd
CY2021Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	93452	usd
CY2022Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	82412	usd
CY2021Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	273924	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	135459	usd
CY2021Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	142274	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	521229	usd
CY2022Q2	us-gaap	Construction In Progress Gross ConstructionInProgressGross	579402	usd
CY2021Q2	us-gaap	Construction In Progress Gross ConstructionInProgressGross	560910	usd
CY2012Q2	chhe	Estimated Total Cost Of Construction EstimatedTotalCostOfConstruction	1860000	usd
CY2012Q2	chhe	Estimated Total Cost Of Construction EstimatedTotalCostOfConstruction	12800000	cny
CY2022Q2	chhe	Construction In Progress Percentage ConstructionInProgressPercentage	0.779	pure
CY2022Q2	chhe	Cost Of Construction In Progress costOfConstructionInProgress	1448567	usd
CY2022Q2	chhe	Cost Of Construction In Progress costOfConstructionInProgress	9702644	cny
CY2022Q2	chhe	Construction In Progress Amount ConstructionInProgressAmount	949040	usd
CY2022Q2	chhe	Construction In Progress Amount ConstructionInProgressAmount	6356767	cny
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3879752	usd
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3671106	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3158021	usd
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3629905	usd
CY2022	us-gaap	Depreciation Depreciation	344919	usd
CY2021	us-gaap	Depreciation Depreciation	393168	usd
CY2022	chhe	Depreciation Expense Charged To Operations DepreciationExpenseChargedToOperations	344919	usd
CY2021	chhe	Depreciation Expense Charged To Operations DepreciationExpenseChargedToOperations	124073	usd
CY2021	chhe	Depreciation Expense Charged To Cost Of Goods Sold DepreciationExpenseChargedToCostOfGoodsSold	269095	usd
CY2022Q2	us-gaap	Accrual For Taxes Other Than Income Taxes Current And Noncurrent AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent	79331	usd
CY2021Q2	us-gaap	Accrual For Taxes Other Than Income Taxes Current And Noncurrent AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent	112767	usd
CY2022Q2	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	133005	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-5050012	usd
CY2021Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-4740824	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1412603	usd
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1963516	usd
CY2022	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P10Y
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	485625	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	485625	usd
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	6759761	usd
CY2021Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	8079761	usd
CY2022Q2	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	23839	usd
CY2021Q2	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	28895	usd
CY2022Q2	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	29835	usd
CY2021Q2	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	34697	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-351016	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2021583	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-73714	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	424532	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Settlements Foreign IncomeTaxReconciliationTaxSettlementsForeign	-7874	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Settlements Foreign IncomeTaxReconciliationTaxSettlementsForeign	392435	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	84522	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-86506	usd
CY2022	chhe	Total Provision For Income Taxes TotalProvisionForIncomeTaxes	2934	usd
CY2021	chhe	Total Provision For Income Taxes TotalProvisionForIncomeTaxes	730461	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	727588	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	727588	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	2934	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	2873	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2934	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2873	usd
CY2022	chhe	Total Provision For Income Taxes TotalProvisionForIncomeTaxes	2934	usd
CY2021	chhe	Total Provision For Income Taxes TotalProvisionForIncomeTaxes	730461	usd
CY2022Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1096936	usd
CY2021Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1018253	usd
CY2022Q2	chhe	Allowance For Doubtful Accounts AllowanceForDoubtfulAccounts	-12192	usd
CY2021Q2	chhe	Allowance For Doubtful Accounts AllowanceForDoubtfulAccounts	-15100	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1084744	usd
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1000220	usd
CY2021Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	2933	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-353950	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	1291122	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.0054
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.0197
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	65539737	shares
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	65539737	shares
CY2021	chhe	Number Of Suppliers NumberOfSuppliers	3	pure
CY2021	chhe	Number Of Customers NumberOfCustomers	6	pure
CY2021	chhe	Concentration Risk Threshold Percentage ConcentrationRiskThresholdPercentage	0.91	pure
CY2022Q2	chhe	Number Of Business Segments NumberOfBusinessSegments	3	pure
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	pure
CY2022Q2	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent		usd
CY2021Q2	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent		usd
CY2022	us-gaap	Interest Expense InterestExpense		usd
CY2021	us-gaap	Interest Expense InterestExpense		usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.0054
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.0197
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	65539737	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	65539737	shares
CY2022	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments		usd
CY2021	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments		usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022	chhe	Payments To Expenditure In Construction In Progress PaymentsToExpenditureInConstructionInProgress		usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2022	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments		usd
CY2021	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments		usd
CY2022	us-gaap	Proceeds From Divestiture Of Interest In Subsidiaries And Affiliates ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates		usd
CY2021	us-gaap	Proceeds From Divestiture Of Interest In Subsidiaries And Affiliates ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates		usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2022	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt		usd
CY2021	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt		usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	chhe	Loan From Related Party For The Construction Of A Facility LoanFromRelatedPartyForTheConstructionOfAFacility		usd
CY2022Q2	us-gaap	Inventory Net Of Allowances Customer Advances And Progress Billings InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings		usd
CY2021Q2	us-gaap	Inventory Net Of Allowances Customer Advances And Progress Billings InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings		usd
CY2022	chhe	Depreciation Expense Charged To Cost Of Goods Sold DepreciationExpenseChargedToCostOfGoodsSold		usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense		usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd

Files In Submission

Name	View Source	Status
0001213900-22-056075-index-headers.html	Edgar Link	pending
0001213900-22-056075-index.html	Edgar Link	pending
0001213900-22-056075.txt	Edgar Link	pending
0001213900-22-056075-xbrl.zip	Edgar Link	pending
chhe-20220630.xsd	Edgar Link	pending
ex23-1_001.jpg	Edgar Link	pending
f10k2022ex23-1_chinahealth.htm	Edgar Link	pending
f10k2022ex31-1_chinahealth.htm	Edgar Link	pending
f10k2022ex31-2_chinahealth.htm	Edgar Link	pending
f10k2022ex32-1_chinahealth.htm	Edgar Link	pending
f10k2022ex4-2_chinahealth.htm	Edgar Link	pending
f10k2022_chinahealth.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img_001.jpg	Edgar Link	pending
img_002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
chhe-20220630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
chhe-20220630_def.xml	Edgar Link	unprocessable
f10k2022_chinahealth_htm.xml	Edgar Link	completed
chhe-20220630_lab.xml	Edgar Link	unprocessable
chhe-20220630_cal.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CHHE
China Health Industries Holdings, Inc. Stock $chhe

2022 Q3 Form 10-K Financial Statement

#000121390022056075 Filed on September 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CHHE China Health Industries Holdings, Inc. Stock $chhe

2022 Q3 Form 10-K Financial Statement

#000121390022056075 Filed on September 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CHHE
China Health Industries Holdings, Inc. Stock $chhe